Dr. Guy van Hazel, Professor of Medicine at the University of Western Australia, discusses updated findings from the SIRFLOX study. Selective internal radiation therapy extended progression-free survival by 8.7 months among metastatic colorectal cancer patients with no extrahepatic metastases; adding bevacizumab had little effect.
You are here
Dr. Peter Gibbs, a medical oncologist at Royal Melbourne Hospital in Australia, says hepatic disease progression among metastatic colorectal cancer patients with liver-dominant metastases was reduced in the SIRFLOX trial when selective internal radiation therapy (SIRT) was added to a standard first-line chemotherapy regimen.
Dr. Cindy Grines of the Detroit Medical Center says the MATRIX trial reaffirmed bivalirudin’s safety and effectiveness despite not meeting its primary endpoint. Mortality and bleeding complications were reduced significantly among angioplasty patients receiving bivalirudin versus unfractionated heparin regardless of vascular access site.
Cardiologist Matt Cavender of Brigham and Women’s Hospital in Boston says that in a study of about 2,000 patients at least 75 years of age, those who received cangrelor prior to percutaneous coronary intervention fared better than those who received clopidogrel, mirroring results in younger patients.
Robert Andtbacka of the University of Utah provides an overview about “very encouraging” studies of oncolytic immunotherapies in melanoma, such as talimogene laherparepvec and coxsackievirus A21. Both injected and non-injected lesions have responded to this approach.